At #AACR24 , we’re presenting data from our pivotal trial in relapsed/refractory multiple myeloma. Read about our latest findings.

As part of our commitment to ongoing research in advanced non-small cell lung cancer (NSCLC), we’ll be at #AACR24 sharing insights on the potential use of machine learning and real-world data to predict results of a key efficacy endpoint.

Sharing a regulatory update on our investigational medicine for two subtypes of B-cell non-Hodgkin lymphoma.

We are proud to announce the U.S. FDA approval of an age expansion treatment for heterozygous hypercholesterolemia (HeFH). This provides a new option for certain people living with this rare, inherited disorder that causes high levels of bad cholesterol. Read more.

At #AAD2024 , we’re on the ground sharing the latest research across 26 abstracts and 8 oral presentations, highlighting data across several dermatologic conditions.

Learn more now at: bit.ly/49YRXe4

The U.S. FDA accepted for priority review the application for our investigational medicine for COPD, a serious, debilitating disease that has not seen new treatment approaches in more than a decade.

CC: Sanofi US

The U.S. Food and Drug Administration (FDA) has accepted our Biologics License Application, granting Priority Review, for our investigational medicine in relapsed/refractory multiple myeloma that has progressed after at least three prior therapies.

The Ministry of Health, Labor and Welfare in Japan has approved medicine for chronic spontaneous urticaria (CSU), providing a new option for certain patients struggling to manage this debilitating skin disease. @Sanofi

We're committed to pushing the boundaries of science in the auditory space to help people living with hearing loss. Our pioneering genetic medicines research and technologies have the opportunity to accelerate potential treatments for hearing disorders. #ARO

Today at #ARO , we presented updated results from the first patient dosed in our Phase 1/2 CHORD trial. These early results offer insight into the potential of gene therapy for the treatment of otoferlin-related and other genetic hearing loss. bit.ly/3OpIkwT

Today we’re grateful to our 13,000 colleagues around the world for helping us achieve another strong quarter and full year of 2023. We’re proud of our scientific advancements, commercial strength of our diversified portfolio and our growing impact for patients.

The European Medicines Agency (EMA) accepted for review the Marketing Authorization Application for our investigational bispecific antibody to treat people living with relapsed/refractory multiple myeloma who have progressed after at least three prior lines of therapy.

Today we announced the formation of Regeneron Cell Medicines with the acquisition of @2Seventybio's pipeline of investigational immune cell therapies. This new R&D unit within Regeneron will advance cell therapies and combination approaches to address cancer and other diseases.

Breaking news: The U.S. FDA approved an age expansion for eosinophilic esophagitis ( #EoE ) medicine to treat more people living with the disease. Sanofi US

A new survey conducted with Cancer Research Institute found that U.S. oncologists feel there are still considerable gaps in the research and treatment of advanced non-small cell lung cancer ( #NSCLC ), despite recent advancements in the space. Click below to learn more.

The U.S. FDA has updated the label for our atopic dermatitis medicine, adding safety and efficacy data specifically for patients with moderate-to-severe hand and foot involvement, a particularly difficult-to-treat subset of the disease. Sanofi US

We believe understanding core biology holds the key to answering fundamental truths about serious diseases. Our latest research explores a key driver of allergies and is the cover feature in Science Translational Medicine.

At #ASH23 , we presented new data in R/R FL, including patient-reported outcomes, underscoring our commitment to progress new treatment options for patients with blood cancer. Learn more at the link below.

Today at #ASH23 , we presented new research in R/R DLBCL including updated data from our pivotal trial. Learn more at the link below.

Visit us at #ASH23 (booth 633) to discover how our team is striving to make a big impact through our efforts in hematology – because we know that for patients living with these difficult-to-treat blood cancers and disorders, every moment matters. bit.ly/3T5GILV